Rheumatoid arthritis (RA) is a debilitating autoimmune disease that affects between 0.2 and 1% of the population [1] [2] [3] . Diagnosis is based on clinical and radiological features and the presence of rheumatoid factor (RF) in the serum. The main serological evidence for RA is the presence of RF. RFs of the immunoglobulin (Ig)-M type are found in up to 80% of rheumatoid sera but its specificity is low since it can be found in the sera of patients with other autoimmune diseases and in a proportion of normal individuals [4] . The search for other diagnostic serological assays has resulted in a number of possible additional or alternative candidates.
Antibodies to the perinuclear factor (APF), a component of human buccal mucosal cells [5] , and to keratin [6] are increased in the sera of RA patients. These two antibodies have subsequently been shown to react with the same protein, (pro)filaggrin [7] . An unusual amino acid, citrulline, formed by the action of the enzyme peptidylarginine deiminase on arginine, has been described as a target for autoantibodies in RA [8] . The antibodies previously described as anti-filaggrin have now been shown to react to citrullinated determinants [8] . This target has been further refined by using a cyclic citrullinated peptide (CCP), to enable rapid detection of antibodies in RA [8, 9] . A recent paper comparing IgM RF and anti-CCP suggests that IgM RF is more sensitive than anti-CCP (75 vs 68%) but that anti-CCP is more specific (96 vs 75%) [10] . Other autoantibodies described in RA are directed at other antigenic components and include RA33 [11] , Sa [12] , calpastatin [13] and p68 [14] .
We have shown by Western blotting that antibodies in sera from patients with RA will bind the stress protein BiP [15] . We subsequently demonstrated that T cells from the synovial fluid of RA, but not from control patients, proliferated to recombinant BiP purified from an Escherichia coli expression system. The proliferation seen was low but reproducible and was not associated with the production of -interferon (IFN). There are increased antibody levels to BiP in the sera of mice with collagen-induced arthritis (CIA) and pristane-induced arthritis (PIA). Furthermore, we have shown that pre-immunization with BiP renders animals resistant to the subsequent induction of CIA and rats to adjuvant arthritis [15, 16] . Collectively, this evidence is suggestive of a role for BiP in the pathogenesis of RA. Blass et al. [17] , who originally described the antigen p68 and subsequently identified it as BiP, have confirmed our data. Antibodies to BiP were detected by Western blotting and RA sera were shown to have elevated levels compared to control sera. Their study, instead of using recombinant protein, used mammalian BiP isolated from HeLa cells.
We now describe the development and validation of an enzymelinked immunosorbent assay (ELISA) to detect antibodies to BiP using the recombinant protein. The ELISA was subsequently used to detect anti-BiP antibodies in a group of patients with RA, patients with other inflammatory joint diseases (OIJD) and normal control patients. We also examined sera from a group of patients sampled before they presented any signs or symptoms of joint disease and when they were diagnosed as having early RA. Paired serum and synovial fluid from a number of patients with RA were also examined.
Materials and methods

Production of BiP
BiP was purified from an E. coli expression system as described previously [15] .
Serum collection
Ninety-six RA sera [18] from the Guy's Hospital rheumatology serum bank were used, with a 2.8:1 female to male ratio. The mean age was 58.2 yr with a range from 24 to 100 yr. The control groups consisted of 51 'other inflammatory joint disease' (OIJD) patients [psoriatic arthritis n ¼ 16, giant cell arteritis n ¼ 1, systemic lupus erythematosus (SLE) n ¼ 2, polymyalgia rheumatica n ¼ 11, ankylosing spondylitis n ¼ 8, palindromic arthritis n ¼ 2, seronegative arthritis n ¼ 2, undifferentiated arthritis n ¼ 1, polyarthritis n ¼ 1, reactive arthritis n ¼ 2, scleroderma n ¼ 1, mixed connective tissue disease n ¼ 1, Behc¸et's disease n ¼ 1, primary Sjo¨gren's syndrome n ¼ 1, inflammatory muscle disease n ¼ 1] and 45 normal controls. The mean age of the OIJD group was 55.2 years and the range 34-100, the female to male ratio was 1.6:1. The mean age of the normal group was 51.8 years with a range of 28-79 and the female to male ratio was 1.8:1
Appropriate ethical committee approval was granted for the taking and storing of serum from patients included in this study. Patient consent was obtained before the collection of blood samples (Guy's Research Ethics Committee no 01/05/01).
Sera from pre-disease RA and early RA Eighty-three individuals fulfilling the classification criteria for RA and who had given blood samples before presenting with any symptoms or signs of joint disease were identified in the Northern Sweden Health and Disease Study Cohort and Maternity Cohort of Northern Sweden. Samples from 382 different control individuals (326 females and 56 males) and 83 cases (69 females and 14 males) were identified for the study. The mean age of the pre-patients when sampled was 48 yr, range 20-67 yr, and of the controls 49 yr, range 19-69 yr, respectively. At their first visit at the Early Arthritis Clinic when RA was diagnosed blood was sampled in 67 (55 females and 12 males) of the original 83 prepatients. Anti-BiP levels were determined blind and the code broken at the end of the study. Comparisons were made between those individuals that went on to develop RA (83) and the remainder of the samples (382).
Synovial fluid
Heparinized synovial fluid from RA patients was received from the Guy's Rheumatology Clinic, centrifuged at 2000 rpm for 10 min to remove cells and was stored at À20 C until used.
Anti-BiP ELISA
ELISA plates (Immunosorp, Nunc) were coated with 10 g/ml human recombinant BiP in 0.1 M NaHCO 3 , pH 8.2. Non-specific binding was blocked by the addition of 10% goat serum (Sigma). 100 l of 1/100 diluted serum was added and the plate incubated overnight at 4 C. Detection antibody (goat anti-human IgG-horse radish peroxidase (Sigma) diluted 1/20 000 in PBS with 1% bovine serum albumin and 0.05% Tween 20) was added to each well. The plates were developed with 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) (Sigma). Plates were read at 450 nm. In all cases one-half of each plate was coated with BiP and the other half coated with buffer alone to control for non-specific binding of serum to the plate. A reference serum (from a patient with RA), known to bind highly to BiP, was chosen and incorporated into each assay to allow meaningful comparisons of different plates and between different experiments. Results are expressed as the specific binding to BiP (as optical density (OD) of BiP-coated wells (mean of two wells) minus the corresponding non-specific OD) as a ratio of the BiP specific binding of the reference serum. To control for anti-E. coli contaminants and the effect of the histidine tag, -galactosidase, produced using the same method as BiP, was used as the coating antigen.
Results
Prevalence of anti-BiP antibodies in RA, other inflammatory joint diseases and healthy controls Figure 1a shows antibody levels to BiP of 96 RA patients and 96 controls from the Guy's Hospital serum bank. There is a significant difference (P ¼ 0.001, Mann-Whitney U-test) between the binding of the RA sera (mean ¼ 0.44, S.D.±0.28) and the control population (mean ¼ 0.29±0.21). When the control data are separated into OIJD and healthy controls, RA sera were significantly different from both the OIJD (P ¼ 0.01) and the normal healthy control sera (P ¼ 0.001). Moreover there is a significant difference between the RA group and other arthritides (reactive arthritis, psoriatic arthritis and osteoarthritis) (mean ¼ 0.44±0.28 vs 0.28±0.19; P<0.001, Student's t-test). To confirm these findings, 60 RA sera were obtained from AGT (Athens, Greece). The results were determined blind, with occasional duplicated samples. The Greek sera showed no significant difference from the Guy's sera (Greek mean 0.48±0.36; Guy's mean 0.44±0.28; P ¼ 0.7, Student's t-test). Moreover the repeat samples showed less than 5% variation (data not shown).
The receiver operating characteristics curve was generated by calculating the specificity and sensitivity of the assay at a range of cut-off values. At a cut-off value set at the upper 95% confidence interval (95% CI) of the control data then the specificity of the assay for RA is 71.0% and the sensitivity 73.0%. In 14 RA and 11 OIJD synovial fluid samples tested (Fig. 1b) , the anti-BiP antibody levels in RA synovial fluid were significantly higher than in OIJD (P ¼ 0.04). The levels of anti-BiP antibody were, however, similar in the RA paired serum and synovial fluid (data not shown). By contrast, there was a significant decrease in the concentration of anti-BiP antibodies in the OIJD synovial fluid compared with their matched serum.
Anti-BiP levels in pre-diagnosis RA sera
In the 98 samples from 83 individuals pre-dating the onset of RA (pre-patients) the prevalence of anti-BiP antibodies was 45% compared with 35% in controls ( 2 ¼ 3.405, P>0.05). When the samples from the pre-patients were stratified for time, samples collected more than 1.5 yr before symptoms showed a sensitivity for anti-BiP antibodies of 40% and a specificity of 70%. In prepatient samples taken less than 1.5 yr before symptoms the sensitivity for anti-BiP antibodies was 55% and the specificity 56%. In patients with early RA the prevalence of anti-BiP antibodies was significantly increased, 66% (44/67), compared with controls ( 2 ¼ 22.72, P<0.001). The frequency of anti-BiP antibodies increased significantly ( 2 for trend ¼ 9.00, P<0.01) during the antedating time (calculated on divided intervals) the closer to the time of disease onset (Fig. 2) . Upon developing antiBiP antibodies, all individuals but five remained positive and the titre further increased significantly until the disease was manifest (Kruskal-Wallis one-way analysis of variance, P<0.01).
Discussion
We have confirmed, by means of a specific ELISA, previously published data [15] , using Western blotting, that levels of antibodies to BiP are raised in the sera of patients with RA. Our original observation was confirmed by Blass et al. [17] using BiP purified from a mammalian cell source. These authors suggested that glycosylation of BiP was necessary for antibody binding. Our data, however, show that this is not necessary since the BiP used in our ELISA is produced in an E. coli expression system and is not glycosylated. A direct comparison, however, of glycosylated and non-glycosylated BiP needs to be performed to resolve this issue. To this end, experiments in collaboration with Professor Burmester are being discussed. We have shown an increase in the levels of anti-BiP antibodies in a cohort of established RA patients at Guy's Hospital. There is a significant increase above the levels found in the sera of control groups, either normal healthy controls or patients with other inflammatory joint diseases. Moreover, this level of antibody was mirrored in a cohort of RA sera from patients with established disease in Athens, suggesting that the presence of anti-BiP antibodies is not confined to racial groups or geographical areas but, rather, is a manifestation of the disease itself. Our data suggest that antibodies to BiP, as measured by this method, have sensitivity for established RA of 73% and a specificity of 71% and for early RA of 66 and 65%, respectively. The paper by Blass et al. [17] gave a sensitivity value of 68% for antibodies to BiP, and a specificity of 96%.
The frequency of anti-BiP antibodies was not significantly different between pre-patients and controls in the samples from northern Sweden. However, our data show an increasing antibody level to BiP as the patient approaches the onset of arthritis. By the time the patient is diagnosed with early RA there is a significant increase in anti-BiP antibodies when compared with controls. These data may provide a potential diagnostic role for anti-BiP antibodies in RA when used in patients with early arthritis.
ELISA used to measure serum antibodies can be affected by a number of factors. Therefore, verification of such an ELISA needs to be performed. One complicating factor which might result in false results is that of non-specific binding of the serum to the plate. To control for this we have calculated our anti-BiP levels by subtracting the non-specific binding (that seen with no antigen, or irrelevant antigen produced in the same expression system as BiP and isolated using the same technique) away from the specific binding, thereby giving a true representation of the anti-BiP levels. Levels of RF, which may affect ELISAs measuring immunoglobulin levels, did not influence anti BiP levels. Correlations between RFs of the IgM, IgG and IgA type and anti-BiP binding showed no link between RF and anti-BiP. Neither does heat aggregated IgG, monomeric IgG or IgM bind in the assay (data not shown).
We also demonstrate anti-BiP antibodies in the synovial fluid of patients with RA at corresponding levels to those seen in the serum. The levels are significantly increased over those seen in control synovial fluid. This would suggest that anti-BiP antibodies are made in both the primary and secondary lymphoid organs as well as the joint. It is of interest to note that IgM RF is found at a higher concentration in the joint fluid, with the implication that there is local production [19] . This has been confirmed by studies demonstrating the presence of RF producing plasma cells in the RA synovial compartment [20] .
The mechanisms that lead to the induction of autoantibodies are still poorly understood, but events during apoptosis may be involved. Rao et al. [21] have proposed that BiP can act as an apoptosis regulator by controlling the cellular response to endoplasmic reticulum stress-induced cell death. They report that BiP can block caspase activation and thereby block caspase-mediated cell death. This is contradicted by the observation that BiP messenger ribonucleic acid is up-regulated during programmed cell death in nerve cells [22] , although this could be as a consequence of the cell's attempt to protect against apoptosis. It is of interest to note that Ro, La and BiP are found in the same small surface apoptotic blebs [23] . Furthermore, Kinoshita et al. [24] have reported that mice, when repeatedly immunized with both Ro52 and Ro60 protein, eventually mount an antibody response against BiP, suggesting an interplay between the proteins. However, we were unable to find a correlation between antibodies to BiP and Ro and La in our studies (data not shown).
In summary, we have developed an ELISA that has shown elevated levels of anti-BiP antibodies in RA. The ELISA is robust and gives a specificity of 71% and a sensitivity of 73% for established RA. Antibodies to BiP are identified in samples predating the onset of RA, although with a low specificity. This study did not attempt to correlate anti-BiP levels with either disease severity or duration of established disease, but both of these parameters are under investigation. We suggest that antiBiP antibodies may be a useful additional autoantibody test in patients with RA.
